Search research articles
Contact Us
Filters
Showing results (191-200 of 205) with videos related to
Page
of 21
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
M Oliveira, C Falato, J M Cejalvo, et al.
ESMO Open
|
September 25, 2025
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer
B Walbaum, O Martínez-Sáez, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2018
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
L Paré, T Pascual, E Seguí, et al.
ESMO Open
|
January 7, 2025
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
L Angelats, L Paré, C Rubio-Perez, et al.
ESMO Open
|
October 1, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial
E Seguí, F Brasó-Maristany, T Pascual, et al.
Acta Otorrinolaringologica Espanola
|
June 12, 2026
Comprehensive Cancer Centre Accreditation: Experience and Achievements of a Head Neck Cancer Unit
F X Avilés-Jurado, I Valduvieco, S Medrano-Martorell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)
E L Mayer, D Hlauschek, M Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
G Villacampa, N M Tung, S Pernas, et al.
ESMO Open
|
June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
M J Naughton, D M Zahrieh, M Gnant, et al.
ESMO Open
|
March 7, 2024
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
M Marín-Aguilera, P Jares, E Sanfeliu, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 205) with videos related to
Sort By:
Page
of 21
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
M Oliveira, C Falato, J M Cejalvo, et al.
ESMO Open
|
September 25, 2025
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer
B Walbaum, O Martínez-Sáez, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2018
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
L Paré, T Pascual, E Seguí, et al.
ESMO Open
|
January 7, 2025
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
L Angelats, L Paré, C Rubio-Perez, et al.
ESMO Open
|
October 1, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial
E Seguí, F Brasó-Maristany, T Pascual, et al.
Acta Otorrinolaringologica Espanola
|
June 12, 2026
Comprehensive Cancer Centre Accreditation: Experience and Achievements of a Head Neck Cancer Unit
F X Avilés-Jurado, I Valduvieco, S Medrano-Martorell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)
E L Mayer, D Hlauschek, M Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
G Villacampa, N M Tung, S Pernas, et al.
ESMO Open
|
June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
M J Naughton, D M Zahrieh, M Gnant, et al.
ESMO Open
|
March 7, 2024
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
M Marín-Aguilera, P Jares, E Sanfeliu, et al.
Page
of 21